GE Haiyi, DING Nan. Pharmaceutical care and literature review of type Ⅱ thrombocytopenia induced by anticoagulant therapy on a patient with acute pulmonary embolism[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(3): 279-282. doi: 10.3969/j.issn.1006-0111.2019.03.018
| Citation:
|
GE Haiyi, DING Nan. Pharmaceutical care and literature review of type Ⅱ thrombocytopenia induced by anticoagulant therapy on a patient with acute pulmonary embolism[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(3): 279-282. doi: 10.3969/j.issn.1006-0111.2019.03.018
|
Pharmaceutical care and literature review of type Ⅱ thrombocytopenia induced by anticoagulant therapy on a patient with acute pulmonary embolism
- 1.
Department of Pharmacy, General Hospital of Shanghai Prison, Shanghai 201318, China;Department of Pharmacy, Changhai Hospital Affiliated to Naval Medical University, Shanghai 200433, China
- 2.
Department of Pharmacy, Changhai Hospital Affiliated to Naval Medical University, Shanghai 200433, China
- Received Date: 2018-12-10
- Rev Recd Date:
2019-01-11
-
Abstract
Objective To explore the key points of pharmaceutical care in patients with thrombocytopenia (HIT) induced by low molecular weight heparin,and to provide reference for clinical pharmacists to participate in the clinical treatment of such patients. Methods Pharmaceutical care was carried out by clinical pharmacists for a patient diagnosed with acute pulmonary embolism who developed progressive thrombocytopenia in the treatment of low molecular weight heparin.To assist clinicians to develop treatment options,literatures published in domestic and international were reviewed and the ADRs relevance of this example were evaluated. Results Pharmaceutical care was applied to the acute pulmonary embolism patient and his platelet count returned to normal eventually. Conclusion Clinical pharmacists should give full play to the expertise of pharmacy specialty,actively participate in the treatment and monitoring of clinical HIT patients,and improve the safety and efficacy of drug therapy.
-
References
|
[1]
|
SALTER B S,WEINER M M,TRINH M A,et al.Heparin-induced thrombocytopenia:a comprehensive clinical review[J].J Am Coll Cardiol,2016,67(21):2519-2532. |
|
[2]
|
PRINCE M,WENHAM T.Heparin-induced thrombocytopaenia[J].Postgrad Med J,2018,94(1114):453-457. |
|
[3]
|
颜明明,刘利月,戴婷婷,等.低分子肝素类药物的临床应用[J].中国医药指南,2018,16(18):39-40. |
|
[4]
|
谷文静,张磊.肝素诱导的血小板减少症研究进展[J].临床血液学杂志,2017,30(1):5-7. |
|
[5]
|
RAUOVA L,AREPALLY G,PONCZ M,et al.Molecular and cellular pathogenesis of heparin-induced thrombocytopenia(HIT)[J].Autoimmun Rev,2018,17(10):1046-1052. |
|
[6]
|
中国医师协会心血管内科医师分会血栓防治专业委员会.肝素诱导的血小板减少症中国专家共识(2017)[J].中华医学杂志,2018,98(6):408-417. |
|
[7]
|
WARKENTIN T E, SAFYAN E L, LINKINS L A. Heparin induced thrombocytopenia presenting as bilateral adrenal hemorrhages[J].N Engl J Med,2015,372(5):492-494. |
|
[8]
|
任静,翟振国,门剑龙.肝素诱导的血小板减少症临床诊疗的循证进展[J].中华医学杂志,2017,97(46):3667-3670. |
|
[9]
|
蒋媛,史桂玲,张惠娟,等.1例低分子肝素钙诱导血小板减少症的药学监护[J].医药导报,2017,36(4):406-409. |
|
[10]
|
SCHINDEWOLF M,SCHWANER S,WOLTER M,et al.Incidence and causes of heparin-induced skin lesions[J].CMAJ,2009,181(8):477-481. |
|
[11]
|
GREINACHER A.Heparin-induced thrombocytopenia[J].N Engl J Med,2015,373(19):1883-1884. |
|
[12]
|
KONSTANTINIDES S V,TORBICKI A,AGNELLI G,et al.Corrigendum to:2014 ESC guidelines on the diagnosis and manangement of acute pulmonary embolism[J].Eur Heart J,2014,36(39):2642. |
|
[13]
|
朱愿超,赵紫楠,梁良,等.北京医院786例患者利伐沙班的应用分析[J].临床药物治疗杂志,2018,16(4):58-61. |
|
[14]
|
郑煜,王齐兵,李晓哗.Ⅱ型肝素诱导血小板减少症的危险因素分析[J].上海医药,2016(37)9:46-48. |
-
-
Proportional views
-
DownLoad: